These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3124166)

  • 41. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
    Leong OK; Wong KE; Tay WK; Gill RC
    Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate.
    Steiner S; Nagy C
    Int Pharmacopsychiatry; 1981; 16(3):184-92. PubMed ID: 7319750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fluphenazine enanthate and fluphenazine decanoate: intramuscular injection and esterification as requirements for slow - release characteristics in dogs.
    Dreyfuss J; Shaw JM; Ross JJ
    J Pharm Sci; 1976 Sep; 65(9):1310-5. PubMed ID: 966144
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low dose fluphenazine decanoate in maintenance treatment of schizophrenia.
    Kane JM; Rifkin A; Quitkin F; Nayak D; Saraf K; Ramos-Lorenzi JR; Klein DF; Sachar EJ
    Psychiatry Res; 1979 Dec; 1(3):341-8. PubMed ID: 233160
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical pharmacokinetics of the depot antipsychotics.
    Jann MW; Ereshefsky L; Saklad SR
    Clin Pharmacokinet; 1985; 10(4):315-33. PubMed ID: 2864156
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasma fluphenazine levels in patients receiving two doses of fluphenazine decanoate.
    Marder SR; Hubbard JW; Van Putten T; Hawes EM; McKay G; Mintz J; May PR; Midha KK
    Psychopharmacol Bull; 1986; 22(1):264-6. PubMed ID: 3726072
    [No Abstract]   [Full Text] [Related]  

  • 47. [Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)].
    Lehmann E; Quadbeck H; Tegeler J; Fararuni M; Heinrich K
    Pharmakopsychiatr Neuropsychopharmakol; 1980 May; 13(3):117-29. PubMed ID: 7393998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fluphenazine decanoate: plasma concentrations and clinical response [proceedings].
    Nasrallah HA; Rivera-Calimlin L; Rogol AD
    Psychopharmacol Bull; 1978 Jul; 14(3):46-7. PubMed ID: 353871
    [No Abstract]   [Full Text] [Related]  

  • 49. Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia.
    McCreadie RG; Dingwall JM; Wiles DH; Heykants JJ
    Br J Psychiatry; 1980 Dec; 137():510-7. PubMed ID: 7011468
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks.
    Carpenter WT; Buchanan RW; Kirkpatrick B; Lann HD; Breier AF; Summerfelt AT
    Am J Psychiatry; 1999 Mar; 156(3):412-8. PubMed ID: 10080557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
    Walker CA
    Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fluphenazine decanoate: a clinical problem?
    Inderbitzin LB; Lewine RR; Gloersen BA; Rosen PB; McDonald SC; Vidanagama BP
    Am J Psychiatry; 1989 Jan; 146(1):88-91. PubMed ID: 2563210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Kong DS; Yeo SH
    Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fluphenazine activity and antipsychotic response.
    Hitzemann RJ; Garver DL; Mavroidis M; Hirschowitz J; Zemlan FP
    Psychopharmacology (Berl); 1986; 90(2):270-3. PubMed ID: 3097710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fluphenazine decanoate. Its steady-state pharmacologic profile and relationship to tardive dyskinesia.
    Glazer WM
    Schizophr Res; 1988; 1(6):425-9. PubMed ID: 3154530
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fluphenazine treatment of DSM-III-R male schizophrenic patients among the Xhosa.
    Landmark J; Merskey H; Cernovsky ZZ
    Can J Psychiatry; 1994 May; 39(4):219-22. PubMed ID: 8044729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term fluphenazine decanoate maintenance dosage requirements of chronic schizophrenic patients.
    Capstick N
    Acta Psychiatr Scand; 1980 Mar; 61(3):256-62. PubMed ID: 7376929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fluphenazine determination in human plasma by a sensitive gas chromatographic method using nitrogen detector.
    Javaid JI; Dekirmenjian H; Liskevych U; Lin RL; Davis JM
    J Chromatogr Sci; 1981 Sep; 19(9):439-43. PubMed ID: 7298790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A double-blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia.
    Russell N; Landmark J; Merskey H; Turpin T
    Can J Psychiatry; 1982 Nov; 27(7):593-6. PubMed ID: 7172160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.